- Strong U.S. demand and new product launches drive first-half sales in Human Pharma
- Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches
- Positive Phase III data for survodutide and pipeline progress strengthen long-term outlook
Boehringer Ingelheim announced ongoing sales momentum during the opening six months of 2026, fueled by robust U.S. performance from heightened demand for JARDIANCE® (empagliflozin) alongside effective new product introductions. Total group net revenue rose 16.2%* to EUR 15.8 billion, with Human Pharma contributing EUR 13.1 billion and Animal Health adding EUR 2.6 billion.
Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim, stated: “The strong uptake of our new products JASCAYD® and HERNEXEOS® demonstrate the worth of the scientific innovation behind these medicines for patients, delivering real advancement in areas with substantial unmet medical need. In a time of accelerated medical discovery, where the limits of what is achievable are constantly expanding, innovation-friendly environments like the United States are crucial in making certain that new therapies reach patients more quickly.”
Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: “Our financial results indicate that, in Human Pharma and Animal Health, we successfully managed a difficult macroeconomic climate and political uncertainties. We stay committed to providing innovative medicines to patients and animals across the globe. Going forward, we must direct our long-term investments toward locations closest to our growth markets and where they can generate the greatest possible impact for patients. This also involves working with governments worldwide to establish a setting that properly acknowledges the value of innovative medicines and guarantees patient access.”
Human Pharma: Growth supported by key launches
Human Pharma revenue expanded 20.1%* to EUR 13.1 billion, underpinned by new product introductions. Established offerings such as JARDIANCE® for chronic kidney disease, type 2 diabetes, and heart failure remained significant growth engines, contributing EUR 5.7 billion in net sales during the first half of the year. The favorable trend for JARDIANCE® was aided by a large and increasing patient population, along with changes in the U.S. pricing and reimbursement landscape, which spurred considerable volume expansion. This pattern aligns with Boehringer’s dedication to preserving ongoing patient access and affordability. Without the JARDIANCE® volume effect, the Human Pharma Business Unit’s growth in the first six months would have matched the broader pharmaceutical market.
The enterprise also observed successful traction for its newest product launches, JASCAYD® (nerandomilast) and HERNEXEOS® (zongertinib), especially in the U.S., as both drugs achieved meaningful momentum owing to the innovation-friendly atmosphere in the U.S., as well as in China and Japan. Simplified procedures and stronger incentives for innovation in those regions cleared the path for rapidly making these breakthrough therapies accessible to patients.
JASCAYD®, indicated for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), experienced significant adoption, reflecting the urgent necessity for new treatment choices in a disease area that has seen limited therapeutic advancement for many years. Following approvals in the United States, China, and Japan, along with Thailand, the United Arab Emirates, the UK, and Brazil, JASCAYD® is awaiting EU approval from the European Medicines Agency (EMA).
HERNEXEOS®, an oral therapy for HER2-mutant advanced non-small cell lung cancer, represented the company’s successful return to oncology after a decade, with launches in the U.S., China, and Japan. The company anticipates that HERNEXEOS® will become accessible to European patients only from 2028, following the availability of Phase III data.
Boehringer continued advancing its late-stage pipeline programs during the first half of 2026, achieving notable progress in oncology and cardio-renal-metabolic diseases. Positive Phase III results for survodutide showed the drug’s capacity to address metabolic and liver health beyond overweight and obesity. Progress with a next-generation triple agonist reinforces Boehringer’s ambition to develop a broad obesity and metabolic health portfolio.
Simultaneously, Boehringer Ingelheim initiated three Phase III oncology trials, strengthening its objective to broaden precision cancer care. The company also moved forward key assets such as obrixtamig, an experimental cancer immunotherapy, and apecotrep, an investigational agent targeting kidney disease. Research momentum stayed strong, with five new compounds entering clinical trials. The Boehringer Human Pharma R&D pipeline encompasses roughly 80 projects.
Animal Health: Focus on new launches and emerging disease outbreaks response
The Animal Health segment posted net sales of EUR 2.6 billion in the first six months of 2026, a 0.4%* rise compared to the prior year. This performance reflected a modestly growing animal health market, accompanied by increased consumer price sensitivity and fewer veterinary visits in several nations.
The company keeps executing its 2026 launch plan, including LENZELTA®, a novel vaccine that improves mastitis prevention in dairy cows and has been introduced in multiple EU countries, and Eko Vet+™ | CANINEBEAT® AI, an AI-driven solution that aids in detecting heart murmurs in dogs, already launched in the U.S., the UK, and Germany. Boehringer Ingelheim also continues to support responses to emerging animal disease outbreaks, such as New World screwworm in the U.S., after receiving Emergency Use Authorizations (EUAs) earlier this year from the U.S. Food and Drug Administration.
The company keeps advancing its R&D pipeline in Animal Health, with strong candidates spanning infectious and non-infectious diseases as well as parasiticides, establishing a solid innovation base for the future in pets, equine, and livestock animals.
Outlook
Looking forward, Boehringer anticipates that adoption of recent launches, upcoming pipeline milestones, and sustained investments in innovation will bolster performance for the remainder of the year and beyond. At the same time, the company will stay focused on steering through a dynamic external environment while preserving a balanced and disciplined approach to growth.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
